Ιατρικά Άρθρα: Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC

Πέμπτη 25 Ιανουαρίου 2018

Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC

Condition: Oropharyngeal Squamous Cell Carcinoma
Interventions: Radiation: Radiation; Drug: Cisplatin; Drug: Durvalumab; Drug: Tremelimumab
Sponsors: Canadian Cancer Trials Group; AstraZeneca
Not yet recruiting

http://ift.tt/2DytMVe

Ιατρικά Άρθρα

Ετικέτες

Πέμπτη 25 Ιανουαρίου 2018

Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Multifunctional Two-Dimensional Bi<sub>2</sub>Se<sub>3</sub> Nanodiscs for Anti-Inflammatory Therapy of Inflammatory Bowel Diseases

Αναζήτηση αυτού του ιστολογίου

Αναφορά κατάχρησης